TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥65 years old.~* Overactive bladder symptoms for at least 3 months prior to study start.~* Eight or more micturitions per 24 hours as confirmed by diary records~Exclusion Criteria:~* Predominant Stress Urinary Incontinence~* Active or recurrent bladder infections~* Other bladder and genital conditions that could be the predominant cause of symptoms or interfere with treatment assessment and success.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: ACTIVE_COMPARATOR): Flexible dose regimen of placebo once daily. The dose can be increased after 4 weeks if clinically indicated. Subsequently the dose can be reduced to the original dose if clinically indicated.
- Fesoterodine (Type: ACTIVE_COMPARATOR): Flexible dose regimen of fesoterodine fumarate 4mg once daily. The dose can be increased to 8mg once daily after 4 weeks if clinically indicated. Subsequently the dose can be reduced to 4mg if clinically indicated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gait Modification Treatment for Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged 50 years and older~* radiographically confirmed medial compartment tibia-femoral knee osteoarthritis~* available for weekly training sessions in the Vancouver British Columbia Canada region~* able to safely perform treadmill walking under therapist supervision~Exclusion Criteria:~* articular cartilage degradation in the lateral tibiofemoral compartment greater than the medial~* inflammatory arthritic condition~* history of knee replacement or arthroscopic knee surgery~* recent use of corticosteroids (oral or via injection)~* inability to ambulate without a gait aid~* non-English speaking~* planning to commence a new treatment approach within the next 4 months

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Gait Modification Group (Type: EXPERIMENTAL): Participants will complete 4 months of a home-based progressive walking program with toe-out gait modification aimed at improving physical activity level. This group will perform continuous treadmill walking during regular sessions with a study therapist and will be instructed to perform a toe-out gait, with the aid of a mirror during walking. Focus will also be on increasing the time and distance of walking. These goals will be emphasized for the home-based portion of the intervention as well.
- Walking Only Group (Type: ACTIVE_COMPARATOR): Participants will complete 4 months of a home-based progressive walking program aimed at improving physical activity level. This group will perform continuous treadmill walking during regular sessions with the study therapist with focus on increasing the time and distance of walking. This goal will be emphasized for the home-based portion of the intervention as well.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of Intramuscular TAK-816 in Healthy Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy Japanese infants.~2. Male or female infants aged 2-6 months (≥2 and \<7 months) at the time of the first dose of investigational product (excluding hospitalized infants).~3. Infants whose parents or legal guardians have agreed to cooperate with the investigator during the study period.~4. The legal guardian signed and dated a written, informed consent form prior to the initiation of any study procedures.~Exclusion Criteria:~1. Any serious acute illness.~2. Any underlying cardiovascular, renal, hepatic, or hematologic disease, and/or developmental disorder.~3. History of possible Haemophilus influenzae type b (Hib) infection.~4. Previously diagnosed immunodeficiency.~5. Documented history of anaphylaxis to any ingredients of the investigational product (e.g., diphtheria toxoid).~6. A history of convulsions.~7. Previous administration of another Hib vaccine.~8. Treatment with any live vaccine during the 27 days before the first dose of TAK-816 or with any inactivated vaccine during the 6 days before dosing.~9. Prior participation in any clinical study or post-marketing clinical study.~10. Previously receipt of blood transfusions, gamma globulin preparations (except monoclonal antibody products not containing any components of Hib as antigens), systemic immunosuppressive therapy, or systemic corticosteroids, or a plan to receive any of these products during the study period.~11. Presence of thrombocytopenia or coagulopathy.~12. Children considered ineligible for the study for other reasons by the investigator or subinvestigator.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 6 Months
- Healthy Volunteers: t

Study Arms:
- TAK-816 0.5 mL (Type: EXPERIMENTAL): Primary immunization: TAK-816 0.5 mL, intramuscular injection, once on Day 1 and every 28 days for 2 intervals (Days 29 and 57). Booster immunization: TAK-816 0.5 mL, intramuscular injection, once, 52 weeks after the third dose of primary immunization.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged 18 years or older at time of informed consent with non-malignant chronic pain experiencing opioid-induced constipation~* Subjects with \< 3 spontaneous bowel movements a week and experiencing bowel symptoms~* Subjects receiving chronic opioid therapy due to non-malignant pain for ≥ 3 months~Exclusion Criteria:~* Evidence of clinically significant gastrointestinal disease~* History of chronic constipation prior to starting analgesic medication or any potential non-opioid cause of bowel dysfunction that may be a major contributor to the constipation~* Severe constipation that has not been appropriately managed such that the subject is at immediate risk of developing serious complications of constipation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo orally once daily for 28 days.
- Naldemedine 0.1 mg (Type: EXPERIMENTAL): Participants received 0.1 mg naldemedine orally once daily for 28 days.
- Naldemedine 0.2 mg (Type: EXPERIMENTAL): Participants received 0.2 mg naldemedine orally once daily for 28 days.
- Naldemedine 0.4 mg (Type: EXPERIMENTAL): Participants received 0.4 mg naldemedine orally once daily for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Pharmacology of FYU-981 (Elder Subjects)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese adult subjects~* 20-35 Years (non-elder groups)~* 65- Years (elder groups)~* Body mass index: \>=18.5 and \<25.0~Exclusion Criteria:~* Subjects with any disease or any history of diseases that might be unsuitable for participation in the clinical study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Male elder subjects (Type: EXPERIMENTAL): Male 65- Years
- Male non-elder subjects (Type: EXPERIMENTAL): Male 20-35 Years
- Female elder subjects (Type: EXPERIMENTAL): Female 65- Years
- Female non-elder subjects (Type: EXPERIMENTAL): Female 20-35 Years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Proposal for Web Based Intervention to Promote the Safe Usage of Dating Applications in Young Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 17-27 years old~* Able to read and understand Chinese~Exclusion Criteria:~* Have a physical impediment (e.g. blindness) to prevent them from accessing the content

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 27 Years
- Healthy Volunteers: t

Study Arms:
- Intervention - Dating application topic (Type: EXPERIMENTAL): The intervention will consist of four short videos with points of discussion, a scenario game, and a risk assessment tool regarding dating application usage.
- Control - Health and exercise topic (Type: PLACEBO_COMPARATOR): The control will consist of four short videos with discussion points and an interaction game regarding exercise and healthy living tips.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Generally healthy, postmenopausal women, aged 40 to less than 65 years~* Intact uterus~* At least 12 months of spontaneous amenorrhea, OR 6 months spontaneous amenorrhea with follicle-stimulating hormone (FSH) levels \> 40 mIU/mL.~Exclusion Criteria:~* Use of oral estrogen-, progestin-, androgen-, or SERM-containing drug products within 8 weeks before screening (12 weeks for the osteoporosis substudy)~* A history or active presence of clinically important medical disease~* Malabsorption disorders

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): BZA 20mg/CE 0.625
- Arm 2 (Type: EXPERIMENTAL): BZA 20mg/CE 0.45
- Arm 3 (Type: ACTIVE_COMPARATOR): CE 0.45mg/MPA1.5mg
- Arm 4 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is at least 18 years of age.~* Patient is scheduled to undergo open abdominal surgery requiring overnight hospital stay (24-hour hospital stay after end of surgery).~* Patient is scheduled to receive general anesthesia.~* Patient is scheduled to receive postoperative medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Genotype 1 HCV infection confirmed a positive test for anti-HCV antibody and detectable serum HCV RNA by PCR Never taken DAAs for HCV Patients must be able to understand and agree to/comply with the prescribed dosing regimens and procedures, report for regularly scheduled study visits, and reliably communicate with study personnel about adverse events and concomitant medications No Liver Cirrhosis Liver fibrosis Metavir F3 APRI \> 1,5 FIB4 \> 3,25~Exclusion Criteria:~Infection with HCV other than GT-1 or subjects with mixed infections of any genotype Liver Cirrhosis Evidence of decompensated liver Subjects Infected with HIV-1 Hepatitis B virus (HBV) coinfection Liver or any other organ transplant (including hematopoietic stem cell transplants) other than cornea and hair Current or known history of cancer Documented or suspected hepatocellular carcinoma, as evidenced by previously obtained imaging studies or liver biopsy Pregnancy or impossibility to use birth control methods by the couple, or breastfeeding Regular use of: erythromycin, clarithromycin, rifampicin, rifabutin, telithromycin, itraconazole, ketoconazole, posaconazole, fluconazole, voriconazole, dexamethasone, cisapride, rifapentine, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, St. John's wort (Hypericum perforatum), silymarin (Silybum marianum) and some antiarrhythmic drugs such as amiodarone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Daclatasvir + Sofosbuvir (Type: EXPERIMENTAL): Daclatasvir 60 mg tablet + Sofosbuvir 400 mg tablet oral dosing once daily for 12 weeks
- Simeprevir + Sofosbuvir (Type: EXPERIMENTAL): Simeprevir 150 mg tablet + Sofosbuvir 400 mg tablet oral dosing once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Volunteers must have a body mass index (BMI = weight in kg/height in m2) between 18 and 35 kg/m2 (inclusive) and body weight not less than 50 kg~* Volunteer must have a glomerular filtration rate (the volume of fluid filtered by the kidney) more than or equal to 90 mL/min/1.73 m2 using the Modification of Diet in Renal Disease calculation~* Fasting blood glucose at screening must be less than 100 mg/dL and the 2 hour plasma glucose following the oral glucose tolerance test (conducted at screening) must be less than 140 mg/dL~Exclusion Criteria:~* History of or currently active illness considered to be clinically significant by the Investigator or any other illness that the Investigator considers should exclude the patient from the study or that could interfere with the interpretation of the study results~* Female volunteer is breast-feeding~* Volunteer has a history of smoking or use of nicotine-containing substances within the previous 2 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: EXPERIMENTAL): Each volunteer will receive a single 200 mg dose of canagliflozin (JNJ-28431754) on Day 1.
- Treatment B (Type: EXPERIMENTAL): Each volunteer will receive a single 300 mg dose of canagliflozin (JNJ-28431754) on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Somatostatin Prevent Post-operation Pancreatic Fistula in Intermediate Risk Patients After Pancreaticoduodenectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 year~2. Patients underwent pancreaticoduodenectomy~3. Fistula Risk Score recommended by ISGPS is intermediate risk~4. Inform consent obtained~Exclusion Criteria:~1. Pervious pancreatic surgery history~2. Received somatostatin or analogues treatment less than 5 half-life periods before surgery~3. Known allergy to somatostatin or mannitol~4. Woman who is pregnant, plan to be pregnant or during lactation period~5. Attended other clinical trials within 30 days~6. All contraindications to somatostatin (Stilamin®)~7. Patients with any serious disease that investigator considers he/she should be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stilamin group (Type: EXPERIMENTAL): Patients in the Stilamin group will be continuous intravenous infusion with the somatostatin in addition to postoperative conventional treatment.
- Control group (Type: NO_INTERVENTION): Patients in the control group will receive the postoperative conventional treatment, without addition of any new medicines.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Participant is 12 to 65 years old at the time of screening~* Participant and/or legal representative has/have provided signed informed consent~* Participant has severe (factor IX (FIX) level \< 1%) or moderately severe (FIX level 1-2%) hemophilia B (based on the one stage activated partial thromboplastin time (aPTT) assay), as tested at screening at the central laboratory~* Participant is previously treated with plasma-derived or recombinant FIX concentrate(s) for a minimum of 150 exposure days (EDs) (based on the participant's medical records); if a verifiable, documented history is unavailable, the participant can be enrolled if s/he has 100-150 EDs to any FIX product that are not fully documented and has participated in Study 050901 for at least 50 EDs to Immunine prior to enrollment (not valid for US and Japan).~* Participant has no evidence of a history of FIX inhibitors~* If the participant is to receive prophylactic treatment, the participant is willing to receive prophylactic treatment over a period of 6 months.~* If the participant is to receive on-demand treatment, the participant has ≥12 documented bleeding episodes requiring treatment within 12 months prior to enrollment and is willing to receive on-demand treatment for the duration of this study.~Main Exclusion Criteria:~* The participant has a history of FIX inhibitors with a titer ≥0.6 Bethesda Units (BU) (as determined by the Nijmegen modification of the Bethesda assay or the assay employed in the respective local laboratory) at any time prior to screening~* The participant has a detectable FIX inhibitor at screening, with a titer ≥0.6 BU as determined by the Nijmegen modification of the Bethesda assay in the central laboratory~* The participant's weight is \< 35 kg or \> 120 kg~* The participant has a history of allergic reaction, eg, anaphylaxis, following exposure to FIX concentrate(s)~* The participant has a known hypersensitivity to hamster proteins or recombinant furin (rFurin)~* The participant has ongoing or recent evidence of a thrombotic disease, fibrinolysis or disseminated intravascular coagulation (DIC)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- BAX 326 (Type: EXPERIMENTAL): Recombinant factor IX (rFIX)
- BeneFIX (Type: ACTIVE_COMPARATOR): Recombinant Factor IX (rFIX)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete